Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Topical treatments for skin cancer.

Cullen JK, Simmons JL, Parsons PG, Boyle GM.

Adv Drug Deliv Rev. 2019 Nov 6. pii: S0169-409X(19)30193-0. doi: 10.1016/j.addr.2019.11.002. [Epub ahead of print]

PMID:
31705912
2.

Kunitz type protease inhibitor from the canine tapeworm as a potential therapeutic for melanoma.

Ranasinghe SL, Rivera V, Boyle GM, McManus DP.

Sci Rep. 2019 Nov 7;9(1):16207. doi: 10.1038/s41598-019-52609-4.

3.

Basimarols A, B, and C, Highly Oxygenated Pimarane Diterpenoids from Basilicum polystachyon.

Tan YP, Xue Y, Savchenko AI, Houston SD, Modhiran N, McMillan CLD, Boyle GM, Bernhardt PV, Young PR, Watterson D, Williams CM.

J Nat Prod. 2019 Oct 25;82(10):2828-2834. doi: 10.1021/acs.jnatprod.9b00522. Epub 2019 Sep 25.

PMID:
31553187
4.

SerpinB2 inhibits migration and promotes a resolution phase signature in large peritoneal macrophages.

Schroder WA, Hirata TD, Le TT, Gardner J, Boyle GM, Ellis J, Nakayama E, Pathirana D, Nakaya HI, Suhrbier A.

Sci Rep. 2019 Aug 27;9(1):12421. doi: 10.1038/s41598-019-48741-w.

5.

C5a receptors C5aR1 and C5aR2 mediate opposing pathologies in a mouse model of melanoma.

Nabizadeh JA, Manthey HD, Panagides N, Steyn FJ, Lee JD, Li XX, Akhir FNM, Chen W, Boyle GM, Taylor SM, Woodruff TM, Rolfe BE.

FASEB J. 2019 Oct;33(10):11060-11071. doi: 10.1096/fj.201800980RR. Epub 2019 Jul 12.

PMID:
31298935
6.

The cubane paradigm in bioactive molecule discovery: further scope, limitations and the cyclooctatetraene complement.

Houston SD, Fahrenhorst-Jones T, Xing H, Chalmers BA, Sykes ML, Stok JE, Farfan Soto C, Burns JM, Bernhardt PV, De Voss JJ, Boyle GM, Smith MT, Tsanaktsidis J, Savage GP, Avery VM, Williams CM.

Org Biomol Chem. 2019 Jul 17;17(28):6790-6798. doi: 10.1039/c9ob01238a.

PMID:
31241113
7.

Stachyonic Acid: A Dengue Virus Inhibitor from Basilicum polystachyon.

Tan YP, Houston SD, Modhiran N, Savchenko AI, Boyle GM, Young PR, Watterson D, Williams CM.

Chemistry. 2019 Apr 17;25(22):5664-5667. doi: 10.1002/chem.201900591. Epub 2019 Mar 29.

PMID:
30924209
8.

Cyclooctatetraene: A Bioactive Cubane Paradigm Complement.

Xing H, Houston SD, Chen X, Ghassabian S, Fahrenhorst-Jones T, Kuo A, Murray CP, Conn KA, Jaeschke KN, Jin DY, Pasay C, Bernhardt PV, Burns JM, Tsanaktsidis J, Savage GP, Boyle GM, De Voss JJ, McCarthy J, Walter GH, Burne THJ, Smith MT, Tie JK, Williams CM.

Chemistry. 2019 Feb 21;25(11):2729-2734. doi: 10.1002/chem.201806277. Epub 2019 Jan 25.

PMID:
30681236
9.

New Casbanes and the First trans-Cyclopropane seco-Casbane from the Australian Rainforest Plant Croton insularis.

Maslovskaya LA, Savchenko AI, Pierce CJ, Boyle GM, Gordon VA, Reddell PW, Parsons PG, Williams CM.

Chemistry. 2019 Jan 28;25(6):1525-1534. doi: 10.1002/chem.201804904. Epub 2019 Jan 2.

PMID:
30601580
10.

Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer.

Ranasinghe SL, Boyle GM, Fischer K, Potriquet J, Mulvenna JP, McManus DP.

PLoS One. 2018 Aug 31;13(8):e0200433. doi: 10.1371/journal.pone.0200433. eCollection 2018.

11.

Corrigendum: Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere.

Chalmers BA, Xing H, Houston S, Clark C, Ghassabian S, Kuo A, Cao B, Reitsma A, Murray CP, Stok JE, Boyle GM, Pierce CJ, Littler SW, Winkler DA, Bernhardt PV, Pasay C, De Voss JJ, McCarthy J, Parsons PG, Walter GH, Smith MT, Cooper HM, Nilsson SK, Tsanaktsidis J, Savage GP, Williams CM.

Angew Chem Int Ed Engl. 2018 Jul 9;57(28):8359. doi: 10.1002/anie.201711161. No abstract available.

PMID:
29975016
12.

Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate.

Barnett CME, Broit N, Yap PY, Cullen JK, Parsons PG, Panizza BJ, Boyle GM.

Invest New Drugs. 2019 Feb;37(1):1-8. doi: 10.1007/s10637-018-0604-y. Epub 2018 Apr 18.

PMID:
29667135
13.

The Aromatic Head Group of Spider Toxin Polyamines Influences Toxicity to Cancer Cells.

Wilson D, Boyle GM, McIntyre L, Nolan MJ, Parsons PG, Smith JJ, Tribolet L, Loukas A, Liddell MJ, Rash LD, Daly NL.

Toxins (Basel). 2017 Oct 27;9(11). pii: E346. doi: 10.3390/toxins9110346.

14.

MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.

Simmons JL, Pierce CJ, Al-Ejeh F, Boyle GM.

Sci Rep. 2017 Sep 7;7(1):10909. doi: 10.1038/s41598-017-11366-y.

15.

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ.

Cancer Res. 2017 Sep 1;77(17):4684-4696. doi: 10.1158/0008-5472.CAN-17-0393. Epub 2017 Jun 26.

16.

Furofuran lignans from the Simpson Desert species Eremophila macdonnellii.

Tan YP, Savchenko AI, Broit N, Boyle GM, Parsons PG, Williams CM.

Fitoterapia. 2018 Apr;126:93-97. doi: 10.1016/j.fitote.2017.06.004. Epub 2017 Jul 15.

PMID:
28596028
17.

Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.

Smith C, Lee V, Schuessler A, Beagley L, Rehan S, Tsang J, Li V, Tiu R, Smith D, Neller MA, Matthews KK, Gostick E, Price DA, Burrows J, Boyle GM, Chua D, Panizza B, Porceddu SV, Nicholls J, Kwong D, Khanna R.

Oncoimmunology. 2017 Jan 4;6(2):e1273311. doi: 10.1080/2162402X.2016.1273311. eCollection 2017.

18.

Ssb1 and Ssb2 cooperate to regulate mouse hematopoietic stem and progenitor cells by resolving replicative stress.

Shi W, Vu T, Boucher D, Biernacka A, Nde J, Pandita RK, Straube J, Boyle GM, Al-Ejeh F, Nag P, Jeffery J, Harris JL, Bain AL, Grzelak M, Skrzypczak M, Mitra A, Dojer N, Crosetto N, Cloonan N, Becherel OJ, Finnie J, Skaar JR, Walkley CR, Pandita TK, Rowicka M, Ginalski K, Lane SW, Khanna KK.

Blood. 2017 May 4;129(18):2479-2492. doi: 10.1182/blood-2016-06-725093. Epub 2017 Mar 7.

19.

NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.

Fane ME, Chhabra Y, Hollingsworth DEJ, Simmons JL, Spoerri L, Oh TG, Chauhan J, Chin T, Harris L, Harvey TJ, Muscat GEO, Goding CR, Sturm RA, Haass NK, Boyle GM, Piper M, Smith AG.

EBioMedicine. 2017 Feb;16:63-75. doi: 10.1016/j.ebiom.2017.01.013. Epub 2017 Jan 16.

20.

Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection.

Montes de Oca M, Kumar R, Rivera FL, Amante FH, Sheel M, Faleiro RJ, Bunn PT, Best SE, Beattie L, Ng SS, Edwards CL, Boyle GM, Price RN, Anstey NM, Loughland JR, Burel J, Doolan DL, Haque A, McCarthy JS, Engwerda CR.

Cell Rep. 2016 Oct 4;17(2):399-412. doi: 10.1016/j.celrep.2016.09.015.

21.

Expression profiling of cutaneous squamous cell carcinoma with perineural invasion implicates the p53 pathway in the process.

Warren TA, Broit N, Simmons JL, Pierce CJ, Chawla S, Lambie DL, Quagliotto G, Brown IS, Parsons PG, Panizza BJ, Boyle GM.

Sci Rep. 2016 Sep 26;6:34081. doi: 10.1038/srep34081.

22.

The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor.

Stark MS, Tom LN, Boyle GM, Bonazzi VF, Soyer HP, Herington AC, Pollock PM, Hayward NK.

Oncotarget. 2016 Aug 2;7(31):49677-49687. doi: 10.18632/oncotarget.10109.

23.

The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses.

Nabizadeh JA, Manthey HD, Steyn FJ, Chen W, Widiapradja A, Md Akhir FN, Boyle GM, Taylor SM, Woodruff TM, Rolfe BE.

J Immunol. 2016 Jun 1;196(11):4783-92. doi: 10.4049/jimmunol.1600210. Epub 2016 Apr 20.

24.

IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.

Le TT, Skak K, Schroder K, Schroder WA, Boyle GM, Pierce CJ, Suhrbier A.

PLoS One. 2016 Apr 21;11(4):e0153975. doi: 10.1371/journal.pone.0153975. eCollection 2016.

25.

Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere.

Chalmers BA, Xing H, Houston S, Clark C, Ghassabian S, Kuo A, Cao B, Reitsma A, Murray CE, Stok JE, Boyle GM, Pierce CJ, Littler SW, Winkler DA, Bernhardt PV, Pasay C, De Voss JJ, McCarthy J, Parsons PG, Walter GH, Smith MT, Cooper HM, Nilsson SK, Tsanaktsidis J, Savage GP, Williams CM.

Angew Chem Int Ed Engl. 2016 Mar 7;55(11):3580-5. doi: 10.1002/anie.201510675. Epub 2016 Feb 5. Erratum in: Angew Chem Int Ed Engl. 2018 Jul 9;57(28):8359.

PMID:
26846616
26.

Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model.

Melino M, Gadd VL, Alexander KA, Beattie L, Lineburg KE, Martinez M, Teal B, Le Texier L, Irvine KM, Miller GC, Boyle GM, Hill GR, Clouston AD, Powell EE, MacDonald KP.

Am J Pathol. 2016 Mar;186(3):524-38. doi: 10.1016/j.ajpath.2015.10.029. Epub 2016 Jan 4.

PMID:
26762581
27.

Novel mouse model for simulating microsurgical tumor excision with facial nerve preservation.

Lim JH, Boyle GM, Panizza B.

Laryngoscope. 2016 Jan;126(1):E1-5. doi: 10.1002/lary.25545. Epub 2015 Aug 8.

PMID:
26257262
28.

Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects.

Gartlan KH, Markey KA, Varelias A, Bunting MD, Koyama M, Kuns RD, Raffelt NC, Olver SD, Lineburg KE, Cheong M, Teal BE, Lor M, Comerford I, Teng MW, Smyth MJ, McCluskey J, Rossjohn J, Stockinger B, Boyle GM, Lane SW, Clouston AD, McColl SR, MacDonald KP, Hill GR.

Blood. 2015 Sep 24;126(13):1609-20. doi: 10.1182/blood-2015-01-622662. Epub 2015 Jul 23.

PMID:
26206951
29.

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.

Stark MS, Bonazzi VF, Boyle GM, Palmer JM, Symmons J, Lanagan CM, Schmidt CW, Herington AC, Ballotti R, Pollock PM, Hayward NK.

Oncotarget. 2015 Jul 10;6(19):17753-63.

30.

Mechanisms contributing to differential regulation of PAX3 downstream target genes in normal human epidermal melanocytes versus melanoma cells.

Bartlett D, Boyle GM, Ziman M, Medic S.

PLoS One. 2015 Apr 16;10(4):e0124154. doi: 10.1371/journal.pone.0124154. eCollection 2015.

31.

Autophagy is required for stem cell mobilization by G-CSF.

Leveque-El Mouttie L, Vu T, Lineburg KE, Kuns RD, Bagger FO, Teal BE, Lor M, Boyle GM, Bruedigam C, Mintern JD, Hill GR, MacDonald KP, Lane SW.

Blood. 2015 May 7;125(19):2933-6. doi: 10.1182/blood-2014-03-562660. Epub 2015 Mar 18.

PMID:
25788702
32.

Ectopic expression of protein kinase C-β sensitizes head and neck squamous cell carcinoma to diterpene esters.

Adams RA, D'Souza MM, Pierce CJ, Korica N, Wallwork B, Parsons PG, Panizza B, Boyle GM.

Anticancer Res. 2015 Mar;35(3):1291-6.

PMID:
25750277
33.

Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models.

Boyle GM, D'Souza MM, Pierce CJ, Adams RA, Cantor AS, Johns JP, Maslovskaya L, Gordon VA, Reddell PW, Parsons PG.

PLoS One. 2014 Oct 1;9(10):e108887. doi: 10.1371/journal.pone.0108887. eCollection 2014.

34.

Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.

Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, Jones L, Crough T, Dasari V, Klein K, Smalley A, Alexander H, Walker DG, Khanna R.

Cancer Res. 2014 Jul 1;74(13):3466-76. doi: 10.1158/0008-5472.CAN-14-0296. Epub 2014 May 4.

35.

Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G-CSF and IL-10.

MacDonald KP, Le Texier L, Zhang P, Morris H, Kuns RD, Lineburg KE, Leveque L, Don AL, Markey KA, Vuckovic S, Bagger FO, Boyle GM, Blazar BR, Hill GR.

J Immunol. 2014 Apr 1;192(7):3180-9. doi: 10.4049/jimmunol.1302315. Epub 2014 Feb 28.

36.

Multimodal polymer nanoparticles with combined 19F magnetic resonance and optical detection for tunable, targeted, multimodal imaging in vivo.

Rolfe BE, Blakey I, Squires O, Peng H, Boase NR, Alexander C, Parsons PG, Boyle GM, Whittaker AK, Thurecht KJ.

J Am Chem Soc. 2014 Feb 12;136(6):2413-9. doi: 10.1021/ja410351h. Epub 2014 Jan 29.

PMID:
24437730
37.

Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.

Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, Bille K, Bahadoran P, Giacchero D, Lacour JP, Boyle GM, Hayward NF, Bertolotto C, Ballotti R.

Oncotarget. 2013 Dec;4(12):2212-24.

38.

Evidence for an alternatively spliced MITF exon 2 variant.

Simmons JL, Pierce CJ, Boyle GM.

J Invest Dermatol. 2014 Apr;134(4):1166-1168. doi: 10.1038/jid.2013.426. Epub 2013 Oct 14. No abstract available.

39.

Histopathological features of clinical perineural invasion of cutaneous squamous cell carcinoma of the head and neck and the potential implications for treatment.

Panizza B, Warren TA, Solares CA, Boyle GM, Lambie D, Brown I.

Head Neck. 2014 Nov;36(11):1611-8. doi: 10.1002/hed.23509. Epub 2013 Dec 18.

PMID:
24115192
40.

Plasticity of melanoma in vivo: murine lesions resulting from Trp53, but not Cdk4 or Arf deregulation, display neural transdifferentiation.

Handoko HY, Boyle GM, Ferguson B, Muller HK, Soyer HP, Walker GJ.

Pigment Cell Melanoma Res. 2013 Sep;26(5):731-4. doi: 10.1111/pcmr.12124. Epub 2013 Jun 20.

PMID:
23724991
41.

Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma.

Bosserhoff AK, Ellmann L, Quast AS, Eberle J, Boyle GM, Kuphal S.

Mol Carcinog. 2014 Aug;53(8):635-47. doi: 10.1002/mc.22018. Epub 2013 Apr 26.

PMID:
23625515
42.

REST negatively and ISGF3 positively regulate the human STAT1 gene in melanoma.

Amalraj J, Cutler SJ, Ghazawi I, Boyle GM, Ralph SJ.

Mol Cancer Ther. 2013 Jul;12(7):1288-98. doi: 10.1158/1535-7163.MCT-12-0923. Epub 2013 Apr 18.

43.

Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.

Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, McGuckin MA, Harris JM, Clements JA.

PLoS One. 2013;8(2):e57056. doi: 10.1371/journal.pone.0057056. Epub 2013 Feb 25.

44.

UVB-induced melanocyte proliferation in neonatal mice driven by CCR2-independent recruitment of Ly6c(low)MHCII(hi) macrophages.

Handoko HY, Rodero MP, Boyle GM, Ferguson B, Engwerda C, Hill G, Muller HK, Khosrotehrani K, Walker GJ.

J Invest Dermatol. 2013 Jul;133(7):1803-12. doi: 10.1038/jid.2013.9. Epub 2013 Jan 15.

45.

Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms.

Quan J, Johnson NW, Zhou G, Parsons PG, Boyle GM, Gao J.

Cancer Metastasis Rev. 2012 Jun;31(1-2):209-19. doi: 10.1007/s10555-011-9335-7. Review.

PMID:
22101806
46.

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.

Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM.

Nature. 2011 Nov 13;480(7375):99-103. doi: 10.1038/nature10630.

47.

Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma.

Bonazzi VF, Nancarrow DJ, Stark MS, Moser RJ, Boyle GM, Aoude LG, Schmidt C, Hayward NK.

PLoS One. 2011;6(10):e26121. doi: 10.1371/journal.pone.0026121. Epub 2011 Oct 20.

48.

Effect of novel marine nutraceuticals on IL-1α-mediated TNF-α release from UVB-irradiated human melanocyte-derived cells.

Muthusamy V, Hodges LD, Macrides TA, Boyle GM, Piva TJ.

Oxid Med Cell Longev. 2011;2011:728645. doi: 10.1155/2011/728645. Epub 2011 Sep 22.

49.

Type I interferons suppress CD4⁺ T-cell-dependent parasite control during blood-stage Plasmodium infection.

Haque A, Best SE, Ammerdorffer A, Desbarrieres L, de Oca MM, Amante FH, de Labastida Rivera F, Hertzog P, Boyle GM, Hill GR, Engwerda CR.

Eur J Immunol. 2011 Sep;41(9):2688-98. doi: 10.1002/eji.201141539. Epub 2011 Aug 8.

50.

Therapy for metastatic melanoma: an overview and update.

Boyle GM.

Expert Rev Anticancer Ther. 2011 May;11(5):725-37. doi: 10.1586/era.11.25. Review.

PMID:
21554048

Supplemental Content

Loading ...
Support Center